Pathology-focused AI company PathAI will present findings on the use of machine learning (ML) to enhance the scoring of nonalcoholic steatohepatitis (NASH) at the 2022 AASLD 2022 Liver Meeting. The AASLD 2022 Liver Meeting is Nov. 4–8 in Washington, D.C., where the company will share five presentations. Boston-based PathAI developed four of them with pharmaceutical collaborators. An…
GSK could pay Arrowhead $1B to develop NASH RNAi therapeutic
Arrowhead Pharmaceuticals (NSDQ:ARWR) has signed an exclusive license agreement with GlaxoSmithKline (NYSE:GSK) related to Arrowhead’s experimental RNA interference (RNAi) therapeutic ARO-HSD. The drug is now the subject of a Phase 1/2 study focusing on the drug’s potential as a treatment for nonalcoholic steatohepatitis (NASH), which involves liver inflammation and can cause cirrhosis and liver failure.…
Terns Pharmaceuticals adds former AstraZeneca CMO to board
The biopharma Terns Pharmaceuticals (NSDQ:TERN) has appointed Dr. Ann E. Taylor to its board of directors. Taylor, who served as AstraZeneca‘s chief medical officer from April 2019 to August 2021, has more than 35 years of experience in drug development. Other notable companies she has worked for include Pfizer, Novartis and AstraZeneca subsidiary MedImmune. Dr.…
Ambys Medicines opens cell therapy manufacturing facility, presents data on liver cell data
Privately-held Ambys Medicines has announced that it has opened a 52,000-ft² facility dedicated to hepatocyte manufacturing. The facility is certified to current Good Manufacturing Practices (cGMP) regulations. The company, based in South San Francisco, California, also presented data on its novel bioreactor manufacturing at the Joint Congress of the International Xenotransplantation Association, IXA-CTRMS-2021. Focused on…
Noninvasive liver exam plays role in fighting viral hepatitis and fatty liver disease
Millions of Americans who are living with hepatitis C virus (HCV) will develop a chronic infection that, if left untreated, can cause serious health problems, including liver disease, cirrhosis, liver failure and liver cancer. More than one-third of HCV-infected individuals progress to advanced fibrosis and cirrhosis, and among those with cirrhosis, about 3–5% per year…
Natural treatment has an antibiotic-like effect on HPV
Natural treatment has an antibiotic-like effect on viruses; CBCD reports publication of a new clinical study of Gene-Eden-VIR/Novirin. Most drugs target symptoms. Antibiotics are different. Antibiotics target the cause of the disease, and as a result, cure the disease. Almost all other drugs, such as those that lower cholesterol or blood pressure, target symptoms. These…